Table 2.
Ultrasonic therapies for cancer treatment with three different FDA-approved drug delivery systems.
| FDA-Approved Drugs | Delivery Vehicles | Cancer Types | Model | Ref. |
|---|---|---|---|---|
| Paclitaxel | Microbubbles | Breast cancer | In vitro/in vivo | [45] |
| Paclitaxel | Microbubbles | Cervical cancer | In vitro/in vivo | [124] |
| Paclitaxel | Microbubbles | Breast cancer | In vitro | [125] |
| Paclitaxel | Microbubbles | Breast cancer | In vivo | [126] |
| Paclitaxel | Microbubbles | Pancreatic cancer | In vitro | [127] |
| Paclitaxel | Microbubbles | Breast cancer | In vitro | [128] |
| Paclitaxel | Microbubbles | Ovarian cancer | In vitro | [129] |
| Paclitaxel | Microbubbles | Prostate cancer | In vitro/in vivo | [130] |
| Paclitaxel | Microbubbles | Endometrium | In vitro | [131] |
| Paclitaxel | Nanobubbles | Lung cancer | In vitro | [132] |
| Paclitaxel | Nanobubbles | Lung cancer | In vitro/in vivo | [133] |
| Paclitaxel | Nanobubbles | Breast cancer | In vitro | [134] |
| Paclitaxel | Nanobubbles | Breast cancer | In vitro/in vivo | [81] |
| Paclitaxel | Nanobubbles | Ovarian cancer | In vivo | [106] |
| Paclitaxel | Nanobubbles | Lung cancer | In vitro | [105] |
| Paclitaxel | Nanobubbles | Prostate cancer | In vivo | [85] |
| Paclitaxel/Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [135] |
| Paclitaxel | Nanobubbles/liposomes | Pancreatic cancer, breast cancer, head and neck cancer | In vitro | [91] |
| Doxorubicin | Microbubbles | Breast cancer | In vivo | [33] |
| Doxorubicin | Microbubbles | Glioma | In vitro/in vivo | [73] |
| Doxorubicin | Microbubbles | Liver cancer | In vitro/in vivo | [136] |
| Doxorubicin | Microbubbles | Pancreatic cancer | In vitro/in vivo | [137] |
| Doxorubicin | Microbubbles | Glioblastoma | In vitro/in vivo | [138] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [135] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [139] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [140] |
| Doxorubicin | Microbubbles | Breast cancer and lung cancer | In vitro/in vivo | [141] |
| Doxorubicin | Microbubbles | Prostate cancer | In vitro/in vivo | [51] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [53] |
| Doxorubicin | Microbubbles | Pancreatic cancer | In vitro/in vivo | [142] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [143] |
| Doxorubicin | Microbubbles | Colon cancer | In vitro | [144] |
| Doxorubicin | Microbubbles | Pancreatic cancer | In vitro/in vivo | [145] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro | [146] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro | [147] |
| Doxorubicin | Microbubbles | Liver cancer | In vitro/in vivo | [148] |
| Doxorubicin | Microbubbles | Melanoma | In vitro/in vivo | [149] |
| Doxorubicin | Microbubbles | Breast cancer and lung cancer | In vitro | [150] |
| Doxorubicin | Microbubbles | Liver cancer | In vivo | [57] |
| Doxorubicin | Microbubbles | Liver cancer | In vitro/in vivo | [151] |
| Doxorubicin | Microbubbles | Liver cancer | In vitro/in vivo | [61] |
| Doxorubicin | Microbubbles | Liver cancer | In vitro/in vivo | [152] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro | [153] |
| Doxorubicin | Microbubbles | Pancreatic cancer | In vitro/in vivo | [67] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro/in vivo | [154] |
| Doxorubicin | Microbubbles | Bladder cancer | In vivo | [155] |
| Doxorubicin | Microbubbles | Breast cancer | In vitro | [156] |
| Doxorubicin | Nanobubbles | Breast cancer | In vitro | [157] |
| Doxorubicin | Nanobubbles | Colon cancer | In vitro/in vivo | [158] |
| Doxorubicin | Nanobubbles | Breast cancer | In vitro/in vivo | [141] |
| Doxorubicin | Nanobubbles | Breast cancer and cervical cancer | In vitro | [159] |
| Doxorubicin | Nanobubbles | Ovarian cancer | In vitro/in vivo | [121] |
| Doxorubicin | Nanobubbles | Breast cancer | In vitro/in vivo | [86] |
| Doxorubicin | Nanobubbles | Breast cancer | In vitro/in vivo | [88] |
| Temozolomide | Nanobubbles | Glioblastoma | In vitro/in vivo | [160] |
| Temozolomide | Liposomes | Glioblastoma | In vitro/in vivo | [161] |
| Temozolomide | Liposomes | Glioblastoma | In vitro/in vivo | [162] |